Based on the breast cancer signaling pathway map, we can observe that curcumin has the ability to exert a wide range of inhibitory effects as a triple target of the RTK-PI3K/AKT-ERK1/2 axis in luminal A/B, HER+ positive, and basal-like/TNBC breast cancers (Figure 4C). This evidence concerns the gene AKT1 and breast cancer.